BiotechTube

Crovalimab + Placebo + Intravenous immunoglobulin therapy

Phase 3Withdrawn
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Guillain-Barré Syndrome

Conditions

Guillain-Barré Syndrome

Trial Timeline

Nov 30, 2022 → Sep 30, 2026

NCT ID
NCT05494619

About Crovalimab + Placebo + Intravenous immunoglobulin therapy

Crovalimab + Placebo + Intravenous immunoglobulin therapy is a phase 3 stage product being developed by Chugai Pharmaceutical for Guillain-Barré Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05494619. Target conditions include Guillain-Barré Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05494619Phase 3Withdrawn

Competing Products

1 competing product in Guillain-Barré Syndrome

See all competitors
ProductCompanyStageHype Score
ANX005 + Intravenous immunoglobulinAnnexonPhase 1
28

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77